Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Crossover Study to Assess the Efficacy, Safety, and Tolerability of SR419 in Patients With Postherpetic Neuralgia (PHN)

NCT05357677 is registered in ClinicalTrials.gov with Shanghai SIMR Biotechnology Co., Ltd. as lead sponsor.

NCT NCT05357677
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05357677 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Crossover Study to Assess the Efficacy, Safety, and Tolerability of SR419 in Patients With Postherpetic Neuralgia (PHN)
Lead sponsor
Shanghai SIMR Biotechnology Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
May 13, 2022
Completion date
January 18, 2023
Enrollment
83 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

postherpetic neuralgia